Main Products/ Services/ Pipelines & Platforms
▪ ALA-1000, a 1-month/ 3-month released buprenorphine injectable for opioid use disorder/ chronic pain ▪ ALA-2000, a sustained release naltrexone injectable for alcohol/ opioid use disorder ▪ ALA-3000, a sustained release ketamine injectable for treatment-resistant depression ▪ ALA-4000, a sustained release apomorphine injectable for Parkinson’s disease
Business Interests
▪ Out-Licensing ▪ Collaborative R&D ▪ Clinical Trial
Contact Info
Renee Liang
R&D Manager
+886-4-2463-7115
alar@alarpharm.com